Carcinoembryonic Antigen Market Research Report - Global Forecast Till 2023

Carcinoembryonic Antigen Market Research Report - Global Forecast Till 2023

ID: MRFR/HC/0288-HCRR | March, 2018 | Region: Global | 81 pages | Half-Cooked Research Reports

Carcinoembryogenic Antigen Market: By Application (Colorectal, Pancreatic, Breast, Lung Cancer) By Sampling (Antecubital, Peritoneal, Pleural, Serebrospinal) and By End User (Hospitals, Diagnostic Centers, Research Centers)- Global Forecast till 2023 

Market Synopsis of Carcinoembryonic Antigen Market

Carcinoembryonic antigen or CEA is a group of glycoproteins produced by the gastrointestinal tissues during the fetal development and is involved in cell adhesion. CEA is not present in the healthy adults, however, cancer patients show concentrations of CEA. Colorectal, pancreatic, breast, lung, and other types of cancers can be diagnosed on the basis of the CEA profiling. However, CEA based diagnostic assays are mostly used for the diagnosis of colorectal cancer.      

According 2017 studies of NCBI, the global burden of colorectal cancer is projected to increase by 60%, which will lead to 2.2 million new colorectal cancer cases and 1.1 million deaths by 2030. The increased prevalence of colorectal cancer will increase the CEA based diagnostic demands, which will boost the market during the forecast period.

Increasing per capita healthcare expenditure, rising global burden of cancers, and improving medical services will drive the market growth during the assessment period. Risk of haematoma and infections by CEA testing and low healthcare expenditures in developing countries will restrain the market growth during the projected period. 

The global carcinoembryonic antigen market is expected to grow 6.7% during the forecast period.

Research Methodology

Carcinoembryonic Antigen Market

Intended Audience

  • Pharmaceutical companies

  • Healthcare service providers

  • Diagnostic centers

  • Research organization

Figure 1           Global carcinoembryonic antigen market, regional analysis, 2016 (% market share)

Carcinoembryonic Antigen Market-

The global carcinoembryonic antigen market has been segmented on the basis of application, sampling, and end user.

Based on the application, the market has been segmented into colorectal, pancreatic, breast, lung cancer, and others.  

Based on sampling, the market has been segmented into antecubital, peritoneal, pleural, serebrospinal, and others.

Based on the end users, the market has been segmented into hospitals, diagnostic centers, research centers, and others.

Regional analysis
The Americas account for the largest market due to high prevalence of colorectal cancer, developed healthcare sector, and high per healthcare expenditures.

Europe holds the second position in the global market. Presence of advanced medical sector and high healthcare expenditures will boost the market growth.

Asia Pacific region will witness the fastest growth due constantly developing healthcare sector. Moreover, increasing per capita income and rising disease burden within the region will boost the market growth.

The Middle East & Africa holds the least market share. The absence of global players within the region and poor economy and healthcare services in the African region will restrain the market growth during the forecasted period.

Key Players  
Some of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.

The report
Global Carcinoembryogenic Antigen Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Table of Content

1.    Report Prologue

2.    Introduction

2.1    Definition

2.2    Scope of the Study

2.3    Research Objective

2.4    Assumptions

2.5    Limitations

2.6    Market Structure

2.7    Market Segmentation 

3.    Research Methodology

3.1    Research Process

3.2    Primary Research

3.3    Secondary Research

3.4    Market Size Estimation

3.5    Forecast Model

4.    Market Dynamics

4.1    Drivers

4.2    Restraints

4.3    Opportunities

4.4    Mega Trends

4.5    Macroeconomic Indicators

5.    Market Factor Analysis

5.1     Value Chain Analysis

5.2     Porter’s Five Forces Analysis

5.3     Demand & Supply: Gap Analysis

5.4    Pricing Analysis

5.5    Investment Opportunity Analysis

5.6    Merger and Acquisition Landscape

5.7    Upcoming trends 

5.7.1     Market Trends

5.7.2     Technological Trends

5.7.3    Insurance & Regulations

5.7.4     Others

6.    Carcinoembryogenic Antigen Market, by Application

     6.1    Introduction

6.2    Colorectal Cancer

6.3    Pancreatic Cancer

6.4    Breast Cancer

6.5    Lung Cancer

6.6    Others

7.    Carcinoembryogenic Antigen Market, by Sampling

     7.1    Introduction

7.2    Antecubital

7.3    Peritoneal

7.4    Pleural

7.5    Serebrospinal

7.6    Others

8.    Carcinoembryogenic Antigen Market, by End User

     8.1    Introduction

8.2    Hospitals

8.3    Diagnostic Centers

8.4    Research Centers

8.5    Others

9.    Carcinoembryogenic Antigen Market, Region

9.1    Introduction

9.2    North America

9.2.1    US

9.2.2    Canada

9.3    Europe

9.3.1    Germany

9.3.2    France

9.3.3    Italy

9.3.4    Spain

9.3.5    UK

9.3.6    Rest of Europe

9.4    Asia

9.4.1    Japan

9.4.2    China

9.4.3    India

9.4.4    Australia

9.4.5    Republic of Korea

9.4.6    Rest of Asia Pacific

9.5    Middle East & Africa

9.5.1    Saudi Arabia

9.5.2    UAE

9.5.3    South Africa

9.5.4    Algeria

9.5.5    Egypt

10.        Conclusion

10.1       Key findings

10.1.1    From CEO’s Viewpoint 

10.1.2    Unmet Needs of the Market 

10.2       Key Companies to Watch

10.3       Prediction of Carcinoembryogenic Antigen Market

11.    Appendix